Innovative Companies Diving into The Neuro Market Ahead of 2021
The Pharma Data
DECEMBER 9, 2020
Vigil’s pipeline strategy is to target these diseases by combining a high-level understanding of microglia physiology, disease genotyping, and patient phenotyping to identify specific genetic variations associated with microglial dysfunction. which will remain a key shareholder. SciNeuro Pharmaceuticals. It’s like taking out the trash.
52 
Let's personalize your content